Marker Therapeutics Inc (MRKR)

[microcapbiotech]

IS THIS CORRECT? JUST READ - Aisling Capital Partners disclosed its initial ownership of 3,500,000 shares of the immunotherapy biotech company. The holding, the rough equivalent of 7.7% of the outstanding stock, cost $8 million to acquire as part of Marker's $70 million private placement financing.

So they paid $2.29 per share??
That don't seem right.